MannKind Corp

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 414

Market Cap: $1.4B

Website

Clinical Trials

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: (Part B) MKND-201
Drug: (Part A) MKND-201

First Posted Date: 2024-08-01

Last Posted Date: 2024-08-06

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 40

Registration Number: NCT06532942

Locations: 🇺🇸
Flourish Research, San Antonio, Texas, United States

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Phase 3

Recruiting

Conditions: Treatment Refractory MAC Lung Disease
MAC Lung Disease
Mycobacterium Infections, Nontuberculous

Interventions: Drug: Clofazimine Inhalation Suspension
Drug: Placebo

First Posted Date: 2024-05-17

Last Posted Date: 2024-12-20

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 234

Registration Number: NCT06418711

Locations: 🇺🇸
University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
🇺🇸
University of California San Francisco Fresno, Fresno, California, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 33 locations

INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Biological: Rapid-acting Insulin Analog
Biological: Afrezza
Biological: Basal Insulin
Biological: insulin degludec

First Posted Date: 2023-06-15

Last Posted Date: 2024-08-09

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 141

Registration Number: NCT05904743

Locations: 🇺🇸
Loma Linda University-Diabetes Treatment Center, Loma Linda, California, United States
🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States

and more 16 locations

Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes

Phase 4

Completed

Conditions: Type 1 Diabetes

Interventions: Biological: Afrezza (insulin human) Inhalation Powder
Device: Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
Biological: insulin degludec

First Posted Date: 2022-02-17

Last Posted Date: 2024-10-18

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 33

Registration Number: NCT05243628

Locations: 🇺🇸
Diabetes Treatment Center, Loma Linda University, Loma Linda, California, United States
🇺🇸
Texas Diabetes and Endocrinology, Austin, Texas, United States

Afrezza® INHALE-1 Study in Pediatrics

Phase 3

Active, not recruiting

Conditions: Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Biological: Rapid-acting Insulin Analog
Biological: Afrezza
Biological: Basal Insulin

First Posted Date: 2021-07-23

Last Posted Date: 2024-11-26

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 319

Registration Number: NCT04974528

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Rocky Mountain Clinical Research, Idaho Falls, Idaho, United States
🇺🇸
Joe DiMaggio Children's Hospital, Hollywood, Florida, United States

and more 36 locations

Afrezza® Dosing Optimization Study

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Combination Product: Afrezza Dose 1
Combination Product: Afrezza Dose 2

First Posted Date: 2021-04-19

Last Posted Date: 2023-09-18

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 20

Registration Number: NCT04849845

Locations: 🇺🇸
Diablo Clinical Research, Walnut Creek, California, United States
🇺🇸
AMCR Institute, Escondido, California, United States

Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

Phase 1

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Treprostinil Inhalation Powder

First Posted Date: 2018-03-14

Last Posted Date: 2018-10-30

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 36

Registration Number: NCT03464864

Locations: 🇺🇸
Investigational Site 441, San Antonio, Texas, United States

Afrezza Safety and Pharmacokinetics Study in Pediatric Patients

Phase 2

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Biological: Afrezza

First Posted Date: 2015-08-18

Last Posted Date: 2021-04-06

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 30

Registration Number: NCT02527265

Locations: 🇺🇸
Diabetes, Obesity, Cardiovascular Clinical Specialists (DOCS), Las Vegas, Nevada, United States
🇺🇸
Le Bonheur Children's Hospital, Memphis, Tennessee, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 10 locations

PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)

Phase 1

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Technosphere Insulin SAR439065 Afrezza®

First Posted Date: 2015-06-30

Last Posted Date: 2017-03-15

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 22

Registration Number: NCT02485327

Locations: 🇩🇪
Investigational Site Number 276001, Mainz, Germany

Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus

Phase 1

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: SAR439065
Drug: Insulin lispro

First Posted Date: 2015-06-12

Last Posted Date: 2017-04-13

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 30

Registration Number: NCT02470637

Locations: 🇩🇪
Investigational Site Number 276001, Neuss, Germany

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy